Age-adjusted recipient pretransplantation telomere length and treatment-related mortality after hematopoietic stem cell transplantation

Blood

Volumn 120, Issue 16, 2012, Pages 3353-3359

  De Latour, Règis Peffault ^a,b   Calado, Rodrigo T ^c,d   Busson, Marc ^e   Abrams, Jeffrey ^c   Adoui, Nadir ^a   Robin, Marie ^a   Larghero, Jèrôme ^a,f   Dhedin, Nathalie ^a   Xhaard, Alienor ^a   Clave, Emmanuel ^e   Charron, Dominique ^a,e   Toubert, Antoine ^a,e   Loiseau, Pascale ^d   Sociè, Gèrard ^a,b,f   Young, Neal S ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b UnitèInserm 728   (France)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e INSERM   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868127395     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-403337     Document Type: Article

References (37)

1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoieticcell transplantation. N Engl J Med. 2010;363(22):2091-2101.
2. Sorror ML. Comorbidities and hematopoietic cell transplantation outcomes. Hematology Am Soc Hematol Educ Program. 2010;2010:237-247.
3. Pavlu J, Kew AK, Taylor-Roberts B, et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood. 2010;115(20):4018-4020.
4. Kanda J, Mizumoto C, Ichinohe T, et al. Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2011;46(2):208-216.
5. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109(10):4586-4588. (Pubitemid 46743431)
6. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361(24):2353-2365.
7. Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin North Am. 2009;23(2):215-231.
8. Korthof ET, Van der Zalm J, Raphael MF, et al. Dyskeratosis congenita: evaluation of immune status and hematopoietic stem cell transplantation. A literature and EBMT data base survey of 75 patients [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118:Abstract 4144.
9. Seligman SJ. Telomere shortening in recipients of bone-marrow transplants. Lancet. 1998;351(9111):1287-1288. (Pubitemid 28181986)
10. Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. Lancet. 1998;351(9097):178-181. (Pubitemid 28037008)
11. Shay JW. Accelerated telomere shortening in bone-marrow recipients. Lancet. 1998;351(9097):153-154. (Pubitemid 28036999)
12. Gadalla SM, Savage SA. Telomere biology in hematopoiesis and stem cell transplantation. Blood Rev. 2011;25(6):261-269.
13. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.
14. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
15. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia-Net. Blood. 2010;115(3):453-474.
16. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075-4086. (Pubitemid 41185176)
17. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res. 2002;30(10):e47.
18. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
19. Scheinberg P, Cooper JN, Sloand EM, Wu CO, Calado RT, Young NS. Association of telomere length of peripheral blood leukocytes with hematopoietic relapse, malignant transformation, and survival in severe aplastic anemia. J Am Med Assoc. 2010;304(12):1358-1364.
20. Mathioudakis G, Storb R, McSweeney PA, et al. Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients. Blood. 2000;96(12):3991-3994.
21. Rufer N, Brummendorf TH, Chapuis B, Helg C, Lansdorp PM, Roosnek E. Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation. Blood. 2001;97(2):575-577. (Pubitemid 32060348)
22. Robertson JD, Testa NG, Russell NH, et al. Accelerated telomere shortening following allogeneic transplantation is independent of the cell source and occurs within the first year post transplant. Bone Marrow Transplant. 2001;27(12):1283-1286. (Pubitemid 32655396)
23. Thornley I, Sutherland R, Wynn R, et al. Early hematopoietic reconstitution after clinical stem cell transplantation: evidence for stochastic stem cell behavior and limited acceleration in telomere loss. Blood. 2002;99(7):2387-2396. (Pubitemid 34525424)
24. Baerlocher GM, Rovo A, Muller A, et al. Cellular senescence of white blood cells in very long-term survivors after allogeneic hematopoietic stem cell transplantation: the role of chronic graft-versushost disease and female donor sex. Blood. 2009;114(1):219-222.
25. Schroder CP, Wisman GB, de Jong S, et al. Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer. 2001;84(10):1348-1353. (Pubitemid 32522103)
26. Ricca I, Compagno M, Ladetto M, et al. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF. Leukemia. 2005;19(4):644-651. (Pubitemid 40521170)
27. Akiyama M, Hoshi Y, Sakurai S, Yamada H, Yamada O, Mizoguchi H. Changes of telomere length in children after hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;21(2):167-171. (Pubitemid 28044010)
28. Widmann T, Kneer H, Konig J, Herrmann M, Pfreundschuh M. Sustained telomere erosion due to increased stem cell turnover during triple autologous hematopoietic stem cell transplantation. Exp Hematol. 2008;36(1):104-110. (Pubitemid 350266972)
29. Rocci A, Ricca I, Dellacasa C, et al. Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir. Exp Hematol. 2007;35(4):673-681. (Pubitemid 46427960)
30. Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol. 2009;27(5):791-798.
31. Gadalla SM, Cawthon R, Giri N, Alter BP, Savage SA. Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging (Albany NY). 2010;2(11):867-874.
32. Bolwell BJ. Are predictive factors clinically useful in bone marrow transplantation? Bone Marrow Transplant. 2003;32(9):853-861. (Pubitemid 37369261)
33. Wong R, Shahjahan M, Wang X, et al. Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2005;11(2):108-114. (Pubitemid 40186207)
34. McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28(11):1878-1887.
35. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A. 1992;89(21):10114-10118.
36. Awaya N, Baerlocher GM, Manley TJ, et al. Telomere shortening in hematopoietic stem cell transplantation: a potential mechanism for late graft failure? Biol Blood Marrow Transplant. 2002;8(11):597-600. (Pubitemid 35446750)
37. Matte CC, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Nat Med. 2004;10(9):987-992. (Pubitemid 39273741)